Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 1:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Allergic Diseases Clear all
Withdrawn Phase 4 Interventional

Benralizumab in the Treatment of Patients With Severe Asthma With ABPA

NCT04108962
View directory record Official record
Conditions
ABPA, Severe Asthma, Allergic Bronchopulmonary Aspergillosis
Interventions
Fasenra, 30 Mg/mL Subcutaneous Solution
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Sep 24, 2026, 1:23 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Analytical Validation of the abioSCOPE Device With an IgE Test Panel: Point-of-Care Precision, Sample Type Comparison and Method Correlation

NCT04401631
View directory record Official record
Conditions
Allergy, Allergic Asthma, Allergy to Cats, Allergy to House Dust, Allergy to Dog Dander (Finding), Allergy Mold, Allergy Cockroach
Interventions
Blood Collection
Device
Lead sponsor
Abionic SA
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Sep 24, 2026, 1:23 PM EDT
Active, not recruiting Early Phase 1 Interventional

FAPI PET for Lung Fibrosis

NCT05365802
View directory record Official record
Conditions
Interstitial Lung Disease, Idiopathic Interstitial Pneumonias, Drug-Induced Pneumonitis, Hypersensitivity Pneumonitis, Radiation Pneumonitis, Pneumoconiosis, Pulmonary Fibrosis
Interventions
68Ga-FAPi-46, Computed Tomography, Positron Emission Tomography, High Resolution Computed Tomography
Drug · Procedure
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 24, 2026, 1:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

CP-481,715 Nickel Allergy Study.

NCT00141180
View directory record Official record
Conditions
Dermatitis, Allergic Contact
Interventions
CP-481,715
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
4
States / cities
Ann Arbor, Michigan • New York, New York • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2006 · Synced Sep 24, 2026, 1:23 PM EDT
Completed Phase 4 Interventional

The Effect of Cetirizine on Bronchoconstriction

NCT03340740
View directory record Official record
Conditions
Allergic Rhinitis, Asthma
Interventions
Cetirizine Hydrochloride 1 MG/ML, Placebo - Concentrate
Drug
Lead sponsor
New York City Health and Hospitals Corporation
Other
Eligibility
6 Years to 20 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Sep 24, 2026, 1:23 PM EDT
Completed No phase listed Observational

Screening Protocol for Genetic Diseases of Allergic Inflammation

NCT00852943
View directory record Official record
Conditions
Eosinophilic Disease, Immune Deficiency, HaTS, Urticaria Anaphylaxis, Elevated IgE Level
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 99 Years
Enrollment
834 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 24, 2026, 1:23 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Aquacel Hypersensitivity Dressing in TJAs

NCT06011629
View directory record Official record
Conditions
Contact Allergic Dermatitis, Adverse Skin Reaction
Interventions
Aquacel dressing
Device
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
457 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 24, 2026, 1:23 PM EDT
Completed No phase listed Observational

Factors That Affect the Development of COPD Symptoms

NCT00740337
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 17, 2018 · Synced Sep 24, 2026, 1:23 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Role of Circulating Innate Lymphoid Cells in Allergic Disorders

NCT03069495
View directory record Official record
Conditions
Allergy, Asthma, Urticaria
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 27, 2023 · Synced Sep 24, 2026, 1:23 PM EDT
Completed Phase 2 Interventional

A Study of MEMP1972A in Patients With Allergic Asthma Inadequately Controlled on Inhaled Steroids And A Second Controller (COSTA)

NCT01582503
View directory record Official record
Conditions
Asthma
Interventions
MEMP1972A, placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
51
States / cities
Birmingham, Alabama • Bakersfield, California • Costa Mesa, California + 46 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 24, 2026, 1:23 PM EDT
Completed Early Phase 1 Interventional

Oral Peanut Immunotherapy for Peanut Allergic Patients

NCT01891136
View directory record Official record
Conditions
Peanut Hypersensitivity
Interventions
Peanut protein
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Year to 16 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Sep 24, 2026, 1:23 PM EDT
Completed Phase 1 Interventional Results available

Development of Cockroach Immunotherapy by the Inner-City Asthma Consortium

NCT01221285
View directory record Official record
Conditions
Asthma, Perennial Allergic Rhinitis
Interventions
German cockroach (Blattella germanica) allergenic extract
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Sep 24, 2026, 1:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Understanding and Diagnosing Allergic Disease in Twins

NCT01613885
View directory record Official record
Conditions
Allergies
Interventions
No Intervention
Other
Lead sponsor
Stanford University
Other
Eligibility
0 Years to 80 Years
Enrollment
340 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2019
U.S. locations
2
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Sep 24, 2026, 1:23 PM EDT
Active, not recruiting Phase 2 Interventional

Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma

NCT07120503
View directory record Official record
Conditions
Asthma (Diagnosis)
Interventions
WIN378, Placebo
Drug
Lead sponsor
Windward Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Los Angeles, California • San Jose, California • Melbourne, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 24, 2026, 1:23 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal Allergic Conjunctivitis Patients

NCT01174823
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
bepotastine besilate ophthalmic solution, placebo comparator ophthalmic solution
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
12 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2020 · Synced Sep 24, 2026, 1:23 PM EDT
Active, not recruiting Phase 4 Interventional Results available

The Effects of Dupilumab on Allergic Contact Dermatitis

NCT03935971
View directory record Official record
Conditions
Allergic Contact Dermatitis
Interventions
Dupilumab
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 24, 2026, 1:23 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Response to Rhinovirus Challenge

NCT02910401
View directory record Official record
Conditions
Asthma, Allergic Rhinitis
Interventions
Rhinovirus (GMP RV16 HRV-16)
Biological
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 40 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Sep 24, 2026, 1:23 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Cutaneous and Systemic Reactions to Metal Implants

NCT02483728
View directory record Official record
Conditions
Dermatitis, Allergic Contact
Interventions
Patch Test
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
2
States / cities
Mineola, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Sep 24, 2026, 1:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Tetrix on Alleviation of Burning,Itching Associated With Lesions of Contact Dermatitis

NCT00646867
View directory record Official record
Conditions
Contact Dermatitis
Interventions
Tetrix, Placebo
Device
Lead sponsor
Coria Laboratories, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 21, 2008 · Synced Sep 24, 2026, 1:23 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy

NCT07675811
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
REGN-2Cat, Freneslerbart, Mevonlerbart, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
8 Years and older
Enrollment
570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 24, 2026, 1:23 PM EDT
Enrolling by invitation Not applicable Interventional

Rate of Allergic Contact Dermatitis and Cosmetic Outcomes

NCT06957444
View directory record Official record
Conditions
Allergic Contact Dermatitis, Osteoarthritis, Hip, Osteoarthritis, Knee
Interventions
Sylke Adhesive Dressing, Exofin Skin Glue, Suture Strip Plus
Procedure
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 80 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 24, 2026, 1:23 PM EDT
Not listed Phase 1 Interventional

Safety of Lymph Node Injection for Allergen Immunotherapy

NCT01982474
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Grass pollen extract, Placebo injection
Biological · Other
Lead sponsor
Amber Patterson
Other
Eligibility
15 Years to 24 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Sep 24, 2026, 1:23 PM EDT
Terminated Phase 2 Interventional Results available

Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy

NCT04056299
View directory record Official record
Conditions
Hen Egg Allergy
Interventions
AR201 powder, Placebo powder
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 26 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
11
States / cities
Little Rock, Arkansas • Rolling Hills Estates, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Sep 24, 2026, 1:23 PM EDT
Withdrawn Phase 4 Interventional

A Pilot Investigation of Ciclesonide When Administered as a Hypotonic Versus an Isotonic Formulation of Ciclesonide Nasal Spray

NCT00793858
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
placebo, isotonic ciclesonide, hypotonic ciclesonide
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2013 · Synced Sep 24, 2026, 1:23 PM EDT